Permaseal

US-based medical technology company Micro Interventional Devices (MID) has secured the CE mark approval for its transapical access and closure device, Permaseal.

Permaseal is a high-speed delivery system that operates on compliant soft-tissue PolyCor anchor technology, which places an implant on the myocardium via a mini-thoracotomy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The implant is made from eight PolyCor anchors and one coated, non-absorbable, green braided polyester surgical suture enabling surgeons closer access to the left-ventricle without having to suture the myocardium.

Following the delivery of the implant, Permaseal closes the access site. The access and closure process is quick, reduces blood loss and simplifies the complex structural heart repair processes.

"Permaseal is the first in a series of products designed to replace the need for suturing in structural heart procedures."

Permaseal facilitates a minimally-invasive procedure which can be repeated multiple times, independent of the operator.

See Also:

MID founder president and CEO Michael Whitman said: "Permaseal is the first in a series of products designed to replace the need for suturing in structural heart procedures.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"We are excited that this technology is now available to our European surgeons and their patients."

The secure transapical access and closure study (STASIS) conducted at five European Sites has validated Permaseal after it was observed that it led to reduced opening time, duration of hospital stay, need of transfusion and 12-month mortality, as well as reducing stroke rates to 0%.

Image: A view of MID’s Permaseal. Photo: PRNewsFoto / Micro Interventional Devices.